COMP <GO>
CRL vs LLY // RETURN ON INVESTED CAPITAL (ROIC)
Charles River Laboratories International Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: CRL 3
— LLY 12
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: LLY
LAST: $359.41 (-4.44%) • MKT CAP: $17.95B
roic
0.40%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
roic
32.36%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRL VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRL | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 0.40% | 32.36% | -31.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 36.4x | +58.58 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 3.10% | 2.30% | +0.80 | CRL | /fcf-yield <GO> |
| Operating Margin | 0.60% | 40.21% | -39.61 | LLY | /operating-margins <GO> |
| Net Profit Margin | -3.60% | 31.90% | -35.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 45.51% | -46.41 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.65 | 9.29 | -5.64 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.77% | +0.63 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.0 | 77.9 | -9.83 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.51 | +0.64 | CRL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 26.3x | -3.25 | CRL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.95B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRL REV | LLY REV | CRL GROSS % | LLY GROSS % | CRL FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.02B | $65.18B | 44.0% | 83.0% | $557.0M | $16.81B |
| FY 2024 | $4.05B | $45.04B | 44.0% | 81.3% | $552.3M | $8.82B |
| FY 2023 | $4.13B | $34.12B | 44.0% | 79.3% | $498.1M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRL // BETA 1.15
LLY // BETA 0.51